US EditionPublished • loading... • Updated
After Two Clinical Trials, Ozempic Fails to Slow the Progression of the Alzhéimer
Summary by Vanguardia
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
MEXICO- In a press release published on the Novo Nordisk website on 24 November, the results of the “phase 3 evoke and evoke+ trials in early symptomatic Alzheimer’s” of his medicine known as Ozempic were released randomly, with a total of 3,808 adults for the purpose of evaluating “the efficacy and safety of oral semaglutide compared to placebo, in addition to the standard of care”, explains Novo Nordisk and continues explaining that “the decis…
Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
